A healthy gut can help improve everything from your emotional state of mind to your immune system. In fact, according to Euromonitor International, “about one-quarter of consumers globally suffer from lower digestive health issues. In half of those cases, consumers claim that this has a moderate or even severe impact on their overall health. Gut health goes far beyond solely digestive health, encompassing immunity support and weight management. Gut health refers to a well-balanced microbiota in the gastrointestinal tract and is shown to impact physical and mental wellbeing. Gut health is also related to numerous diseases, such as diabetes, obesity or autoimmune disease, and recent research even suggests an impact on mood due to the so-called gut-brain axis.” As consumers wake up to the benefits of a healthier gut, it could help create a $71.95 billion opportunity, says Fortune Business Insights. It could also be a major catalyst for companies like Psyched Wellness (CSE:PSYC)(OTC:PSYCF), Seres Therapeutics Inc. (NASDAQ:MCRB), Synlogic Inc. (NASDAQ:SYBX), Bristol Myers Squibb Co. (NYSE:BMY), and Codexis Inc. (NASDAQ:CDXS).
Psyched Wellness Just Hired National Research Council of Canada to Test AME-1
Psyched Wellness Ltd. (CSE:PSYC)(OTC:PSYCF), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has contracted the National Research Council of Canada (NRC), an agency of the Government of Canada. The NRC specializes in providing vital scientific and technological services to the research and industrial communities of Canada. The NRC was hired to provide their expertise in biomedical nanotechnology, but all the results of the research will belong to Psyched, and the NRC does not endorse the findings or Psyched products.
This contract will be divided into 3 objectives over a period of 2 years to further preliminary findings indicating anti-inflammatory and antioxidant properties in addition to the study of potential neuroprotective roles of the AME-1 extract. This study is the first successive one to further explore the neuroprotective, anti-inflammatory, and antioxidant nature of the AME-1 extract from the Amanita Muscaria mushroom concentrating on gut health and neuroprotection. Gut health can be impaired and lead to inflammation thus promoting a chronic condition of the gut lining and impairment of barrier function of the digestive tract. This is significant as gut health and immunity promotion is significant for the health and wellness of an individual. Neuroprotection is the preservation of neuronal structure or the rate of function. Preliminary evidence of a neuroprotective role of AME-1 would be a key initial step in the discovery of a new novel health and wellness property of the Amanita Muscaria mushroom.
“This investigative study will reveal key nutritional systematic and functional properties of the AME-1 extract. The Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach using modern scientific methods to help understand the functional neuroprotective and immune properties of AME-1,” says Brian Tancowny, scientific advisor to Psyched.
“We are very proud to announce this agreement with the NRC, the results of this study will further demonstrate the tremendous potential with believe we have with AME-1 for people’s health and wellness.” says Jeffrey Stevens, CEO of the Company.
Other related developments from around the markets include:
Seres Therapeutics Inc., a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, reported first quarter 2021 financial results and provided business updates. “We continue to make steady progress across our broad microbiome pipeline and we look forward to an eventful remainder of the year with important clinical milestones,” said Eric Shaff, President and Chief Executive Officer of Seres. “Our SER-287 ECO-RESET Phase 2b study in mild-to-moderate ulcerative colitis patients is fully enrolled and we anticipate topline clinical results in mid-year. Following successful SER-109 Phase 3 pivotal results in patients with recurrent C. difficile infection, we continue to enroll an open label study to expand our safety database. We are very pleased with the pace of study enrollment and we anticipate achieving target enrollment during the third quarter of 2021. Completion of the required SER-109 safety database will support a Biologics License Application (BLA) filing, and potentially pave the way for SER-109 to become the first-ever FDA-approved microbiome therapeutic.”
Synlogic Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the Company will release its first quarter 2021 financial results before the market opens on Thursday, May 13. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.
Bristol Myers Squibb Co. announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, based on results from the CheckMate -274 trial. The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 3, 2021. “After patients undergo surgery for muscle-invasive urothelial carcinoma, they continue to face uncertainties given the high rate of disease recurrence and the lack of safe and effective treatment options,” said Dana Walker, M.D., M.S.C.E., vice president, development program lead, genitourinary cancers, Bristol Myers Squibb. “Based on the ground-breaking disease-free survival results from CheckMate -274, we believe Opdivo has the potential to change the future of treatment for muscle-invasive urothelial carcinoma. We look forward to working with the FDA towards the goal of bringing the first adjuvant immunotherapy option to these patients in the U.S.”
Codexis Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2021 and provided a business update. “Codexis’ growth drivers are continuing to accelerate, and we began 2021 with strong momentum, especially in higher margin product sales within our Performance Enzymes segment,” said John Nicols, Codexis President and CEO. “Our Life Science Tools business continues to grow rapidly, with initial sales of our Codex® HiCap RNA polymerase, dozens of potential customer trials of our Codex® HiFi DNA polymerase, and excellent traction with new customer partnered Life Science Tools R&D programs. We continue to diversify our Sustainable Manufacturing business, with a more profitable mix of pharmaceutical products, and a growing presence in the faster-to-market food and industrial space. Our high-value Biotherapeutics pipeline is advancing across multiple programs, and we are on track to move our second asset into clinical studies later this year. Leveraging the power of our CodeEvolver® platform, Codexis is engineering enzymes that are enabling and delivering the promise of synthetic biology to improve the health of people and the planet.”
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Psyched Wellness Ltd. by Psyched Wellness Ltd. We own ZERO shares of Psyched Wellness Ltd. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
